DART Trial Shows Combination Immunotherapy Effective in Rare Cancer Patients with Brain Metastases
Key Insights
The DART trial (NCI/SWOG S1609) represents the largest immunotherapy study in rare cancer (search) patients, demonstrating that combination nivolumab plus ipilimumab maintains efficacy regardless of prior anti-PD-1/PD-L1 (search) exposure.
Brain metastases (search) patients showed comparable safety and activity profiles with the combination immunotherapy, challenging the common practice of excluding these patients from clinical trials.
The multicenter basket trial provides crucial evidence that rare cancer (search) patients with brain metastases (search) need and can benefit from immunotherapy treatment options.
The DART trial (NCI/SWOG S1609), the largest immunotherapy study conducted in rare cancer (search) patients, has demonstrated that combination immune checkpoint inhibitor therapy with nivolumab plus ipilimumab remains effective regardless of patients' previous exposure to anti-PD-1/PD-L1 (search) treatments. The findings, published in JCO Oncology Advances, challenge current treatment paradigms and provide new hope for patients with limited therapeutic options.
Prior Immunotherapy Exposure Does Not Compromise Efficacy
The study, led by researchers including Dr. Razelle Kurzrock from the Medical College of Wisconsin, found that patients who had previously received anti-PD-1/PD-L1 (search) therapy still responded to the nivolumab plus ipilimumab combination. This finding is particularly significant for rare cancer (search) patients, who often exhaust standard treatment options and may have received prior immunotherapy.
The research team, including Megan Othus, Sandip P. Patel, Young Kwan Chae, and Eliana Dietrich, analyzed outcomes from this comprehensive multicenter basket trial to determine whether prior checkpoint inhibitor exposure affected treatment responses.
Brain Metastases Patients Show Comparable Outcomes
In a related analysis published in Clinical Cancer Research, the DART trial investigators examined the efficacy and safety of nivolumab and ipilimumab specifically in rare cancer (search) patients with brain metastases (search). The study, authored by Manmeet S. Ahluwalia, Sophie Solomon, and colleagues, revealed that brain metastases did not compromise either the safety or activity of the combination immunotherapy.
"Can we stop excluding brain Mets from clinical trials. These patients need therapy. DART showed that brain Mets did not compromise safety or activity," noted Dr. Kurzrock, highlighting the clinical significance of these findings.
Implications for Clinical Trial Design
The results from both analyses suggest that current practices of excluding patients with brain metastases (search) from clinical trials may be unnecessarily restrictive. The DART trial demonstrated that these patients can safely receive and benefit from combination immunotherapy, providing evidence that could reshape eligibility criteria for future studies.
The multicenter basket trial design allowed researchers to evaluate the combination therapy across multiple rare cancer (search) types, providing broader insights into the treatment's potential applications. This approach is particularly valuable for rare cancers, where individual tumor types may have insufficient patient numbers for dedicated trials.
Advancing Treatment Options for Underserved Populations
The DART trial findings represent a significant advancement for rare cancer (search) patients, a population that historically has limited access to novel therapies. By demonstrating that combination immunotherapy remains effective even after prior checkpoint inhibitor exposure and in patients with brain metastases (search), the study expands potential treatment options for these underserved patients.
The research was conducted through the National Cancer Institute and SWOG Cancer Research Network, reflecting the collaborative effort required to study rare cancers effectively. Dr. Kurzrock, who serves as Founding Director of Michels Rare Cancers Research Laboratories and Co-Founder and Board Member at CureMatch (search), has been instrumental in advancing research in this challenging therapeutic area.